References
- . National Osteoporosis Foundation. Fast facts on osteoporosis [fact sheet]. http://www.nof.org/osteoporosis/diseasefacts.htm. Accessed February 1, 2010
- . Sambrook P. Compliance with treatment in osteoporosis patients—an ongoing problem. Aust Fam Physician. 2006;35(3):135–137
- . Siris ES, Harris ST, Rosen CJ, . Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81(8):1013–1022
- . Reid IR, Miller P, Lyles K, . Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med. 2005;353(9):898–908
- . Reclast (zoledronic acid) injection [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp: 2009
- . McClung M, Miller P, Recknor C, . Zoledronic acid for the prevention of osteoporosis in postmenopausal women with low bone mass. Obstet Gynecol. 2009;114(5):999–1007
- . Orwoll E, Miller P, Adachi J, . Once-yearly I.V. zoledronic acid 5 mg versus weekly oral alendronate 70 mg in men with osteoporosis. In: ENDO 2009Abstracts2View Online. Abstract OR13-3. Chevy Chase, MD: The Endocrine Society; 2009. http://www.endo-society.org/endo09/. Accessed February 1, 2010
- . Reid DM, Devogelaer JP, Saag K; HORIZON investigators.Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy randomised controlled trial. Lancet. 2009;373(9671):1253–1263
- . Delmas PD, Adami S, Strugala C, . Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. 2006;54(6):1838–1846